Streetbeat News

Price Targets

XYL

RBC Capital analyst Deane Dray has maintained an Outperform rating on Xylem (NYSE:XYL) and increased the price target from $120 to $140.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:15 pm

EMR

Mizuho analyst Brett Linzey upgraded Emerson Electric (NYSE:EMR) from Neutral to Buy and set a price target of $118. This upgrade suggests a positive outlook for Emerson Electric's stock performance.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:14 pm

FCX

Raymond James analyst Brian MacArthur has maintained an Outperform rating on Freeport-McMoRan (NYSE:FCX) and increased the price target from $42 to $43.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:13 pm

OMF

Wells Fargo analyst Michael Kaye has maintained an Equal-Weight rating on OneMain Holdings (NYSE:OMF) and increased the price target from $43 to $48.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:11 pm

PFG

Evercore ISI Group analyst Thomas Gallagher upgraded Principal Financial Group (PFG) from Underperform to In-Line and increased the price target from $82 to $83.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:11 pm

XRTX

Alliance Global Partners analyst James Molloy has reaffirmed a Buy rating on XORTX Therapeutics (NASDAQ:XRTX) and increased the price target from $9 to $14, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:09 pm

PROF

Alliance Global Partners analyst Ben Haynor has maintained a Buy rating on Profound Medical (NASDAQ:PROF) but has reduced the price target from $14.25 to $12.75.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:05 pm

FTRE

Fortrea Holdings (NASDAQ:FTRE) has been analyzed by 5 analysts in the last three months, with ratings ranging from bullish to indifferent. The average 12-month price target for FTRE has increased by 19.99% to $38.00, with a high estimate of $44.00 and a low of $32.00. Analysts from Jefferies, Citigroup, Evercore ISI Group, and Barclays have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Fortrea Holdings, a late-stage CRO spun off from LabCorp, has shown revenue growth and a strong net margin but faces challenges with ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 2:00 pm

PTC

PTC (NASDAQ:PTC) has been the subject of diverse analyst ratings over the past three months, with 3 somewhat bullish and 1 indifferent rating. The average 12-month price target for PTC has been raised to $177.5, reflecting a 19.67% increase from the previous target of $148.33. Analysts from JP Morgan, Oppenheimer, and Piper Sandler have raised their price targets, with the highest being $200. PTC specializes in high-end software solutions and has shown a revenue growth of 7.62% as of September 30, 2023. However, it faces challenges with below-average net margin, ROE, and ROA, despite a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 2:00 pm

ALV

Four analysts have recently reviewed Autoliv (NYSE:ALV), with mixed opinions. The average 12-month price target is now $109.25, up from $105.25, with a high of $142.00 and a low of $95.00. Goldman Sachs analyst Philipp Konig raised the target to $142.00 from $126.00, Wells Fargo's Colin Langan to $100.00 from $99.00, Barclays' Dan Levy to $100.00 from $97.00, while Citigroup's Itay Michaeli lowered it to $95.00 from $99.00. Autoliv is a leader in passive safety components for the auto industry, with the Americas being its largest market. The company shows strong revenue growth but below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 2:00 pm